nsclc 中文意思是什麼

nsclc 解釋
非小細胞肺癌
  1. Methods 18 patients with terminal nsclc received alimta and were observed on the harmful said effects, and then were given corresponding nursing

    方法18例晚期非小細胞肺癌患者接受力比泰治療，觀察其副作用並實施相應護理措施。
  2. Keyword : zd1839 nsclc disease control rates adverse events

    關鍵詞： zd1839非小細胞肺癌控制率不良事件。
  3. Detection of micrometastasic tumor cells in lymphadenectomy specimens of patients with nsclc by real - time rt - pcr

    技術檢測肺癌淋巴結的隱匿性微小轉移
  4. Non - small cell lung cancer, nsclc

    目的探討氨基酸腸外營養對非小細胞肺癌
  5. Results sixteen genes that correlated with survival among patients with nsclc were identified by analyzing microarray data and risk scores

    結果：通過對微點陣數據和風險評分的分析， 16個與非小細胞肺癌患者的存活率有相關性的基因被鑒別出來。
  6. Objective to explore the nursing of harmful side effects of alimta in treating terminal nsclc

    目的探討新藥力比泰治療晚期非小細胞肺癌毒副反應的對癥護理措施。
  7. Study objectives : regional lymph node ( ln ) involvement affects the prognosis of patients with surgically resected non - small cell lung cancer ( nsclc )

    目的：區域淋巴結（ ln ）情況影響手術切除非小細胞肺癌（ nsclc ）患者的預后。
  8. It is important to emphasize that we now have ample evidence that chemotherapy prolongs survival in patients with advanced nsclc

    首先需強調的是，我們目前有充分的證據表明化療可以延長晚期nsclc患者的生存期。
  9. Baron mg, felie j, ciron gg, et al. phase trial of mintomycin, vinorelloebine and cisplatin in nonsmallcell lung cancer ( nsclc ) j. proc am soc clin oncol, 1995, 14 : 3738

    張相茹，孫燕，孫維紅，等.去甲長春花堿加順鉑治療晚期非小細胞肺癌42例j .中華腫瘤雜志， 1998 ， 20 （ 1 ） : 6062
  10. Patients diagnosed with nsclc that is too advanced to be cured can be given palliative therapies to ease pain and discomfort, including radiation. lung cancer is by far the biggest cancer killer globally

    醫生們通常會給那些病情發展到晚期無法治愈的非小細胞肺癌患者實施包括放射療法在內的治療，以減輕癌癥帶來的疼痛和不適。
  11. Background ： current staging methods are inadequate for predicting the outcome of treatment of non ? small - cell lung cancer ( nsclc )

    背景：目前的分期方法尚不足以預測非小細胞肺癌的治療效果。
  12. A randomized phase ii study on combination of gemcitabine plus cisplatin versus gemcitabine plus etoposide was done between 1997 and 1999 on 89 patients with stage iiib or iv nsclc

    在1997至1999年間，腫瘤學系使用新的抗癌藥物gemcitabine結合cisplatin或etoposide ，進行第二期臨床測試，參與測試的有89名nsclc第iiib期或iv期病人。
  13. " our data show that close to 1 percent of patients with nsclc have prolonged survival with doses of palliative radiation therapy that would not normally be considered sufficient for long - term disease control, " they wrote

    研究人員表示： 「我們的數據顯示，有大約1的非小細胞肺癌患者在接受小劑量的放射療法后，其倖存期都有所延長。
  14. Conclusions our five - gene signature is closely associated with relapse - free and overall survival among patients with nsclc

    結論：我們的五個基因標記與非小細胞肺癌患者的無復發及總生存率密切相關。
  15. Conclusions it is very important for improving the quality of life of the patients with terminal nsclc and received alimta to perform nursing intervention in time

    結論力比泰治療晚期非小細胞肺癌患者時，及時進行護理干預和對癥處理至關重要，能有效地提高患者的生活質量。
  16. Now it is mainly used as second - line or third - line therapy for nsclc in many countries

    目前它主要用於終末期非小細胞肺癌的二線和三線治療。
  17. We developed a five - gene signature that is closely associated with survival of patients with nsclc

    我們發現了一個五基因標記與非小細胞肺癌的生存率有密切的關系。
  18. Nsclc, the most common type of lung cancer, has an average five - year survival rate of only 40 percent. the five - year survival rate in advanced disease is only about 15 percent

    非小細胞肺癌患者的平均5年倖存率僅為40 ，而那些晚期患者的5年倖存率只有大約15 。
分享友人
分享到 Line

分享到臉書